<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6385">
  <stage>Registered</stage>
  <submitdate>21/03/2017</submitdate>
  <approvaldate>21/03/2017</approvaldate>
  <nctid>NCT03091764</nctid>
  <trial_identification>
    <studytitle>Evaluation of a Patient-Reported Symptom Index for NMIBC</studytitle>
    <scientifictitle>Psychometric Evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: Field Testing</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>APP1103036</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Superficial Bladder Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bladder - transitional cell cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>NMIBC Patient High Risk - Patients requiring intravesical Bacillus Calmette-Gu√©rin (BCG) (immunotherapy), which starts with 6 week induction treatment and continues with maintenance for 1 to 3 years

NMIBC Patient Intermediate Risk - Patients requiring intravesical therapy which lasts between 6 weeks to 3 years

NMIBC Patient Low Risk - Patients receiving frequent cystoscopies, possible tumour resections and single instillations of postoperative chemotherapy

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>NMIBC-SI - non-musclue invasive bladder cancer symptom index (questionnaire being developed and evaluated in this study)</outcome>
      <timepoint>Field test 1: once only (cross-sectional). Field test 2: four time-points over 1 year (longitudinal)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>QLQC-30 - EORTC cancer quality of life questionnaire</outcome>
      <timepoint>Field test 2: four time-points over 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BLS-24 - EORTC superficial bladder cancer questionnaire</outcome>
      <timepoint>Field test 2: four time-points over 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Field test 1:

        

          -  diagnosed NMIBC

          -  Adult (&gt;18yrs)

          -  able to read and understand English

          -  undergoing active treatment (i.e. one week after tumour resection or intravesical
             therapy) or completed final treatment for NMIBC within the last week</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  unconscious or confused

          -  have cognitive impairment

          -  unable to speak, read and/or write in English

          -  diagnosed with muscle invasive disease

          -  unable to provide informed consent

        Field test 2:

        Inclusion Criteria:

          -  diagnosed NMIBC

          -  Adult (&gt;18yrs)

          -  able to read and understand English

          -  after imaging or flexible cystoscopy but before endoscopic resection (i.e. before
             active treatment)

        

          -  unconscious or confused

          -  have cognitive impairment

          -  unable to speak, read and/or write in English

          -  diagnosed with muscle invasive disease

          -  unable to provide informed consent

          -  currently undergoing active treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational [Patient Registry]</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>The Urological Cancer Centre, Westmead Specialist Centre - Westmead</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Mater Misericordiae Limited - South Brisbane</hospital>
    <hospital>Monash Health - East Bentleigh</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3165 - East Bentleigh</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6150 - Murdoch</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Urogenital and Prostate trials Group (ANZUP)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council NSW</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project will develop and evaluate a patient-reported symptom index to assess the impact
      of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and
      side effects. The symptom index will provide a method for assessing treatments from the
      patient's perspective; help healthcare professionals make better informed treatment
      decisions, and provide a method to be able to effectively evaluate treatments for non-muscle
      invasive bladder cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03091764</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Manish Patel, MBBSMMed,PhD</name>
      <address>University of Sydney</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Claudia Rutherford, PhD</name>
      <address />
      <phone>+61 2 8627 1583</phone>
      <fax />
      <email>claudia.rutherford@sydney.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>